Grail's Commercial Performance: Exploring the Growth Challenges in Early Cancer Screening

The third day of the JPM conference witnessed Grail's announcement of its 2023 full-year revenue, which reached $93 million, representing a 68% YoY increase. This aligns with Illumina's revenue guidance, as they had previously projected a 64% growth in Grail's 2023 revenue. However, upon closer examination, Grail's revenue growth has been stagnant for four consecutive quarters since Q4 2022. The CEO attributed the significant Q4 2023 revenue of $30 million to the critical period when Grail was being divested from Illumina, highlighting the need for impressive financial data during that time. Despite being hailed as the king of early cancer screening, Grail's commercial achievements have fallen short. This raises the question of why Grail's growth has been less impressive compared to other screening products, like Cologuard, which have shown steep growth curves.

The 68% Revenue Growth: A Closer Look
Grail's journey in the field of pan-cancer screening has been accompanied by substantial funding, with over $2 billion raised since its establishment in 2015. This robust financial support has propelled Grail ahead in the development of comprehensive cancer screening products, culminating in the successful launch of their first commercial product in 2021. Initially, Grail experienced rapid growth. However, since Q4 2022, their revenue growth has gradually slowed down, with four consecutive quarters of either minimal or negative revenue growth: $23 million, $20 million, $22 million, and $20.7 million.

During the JPM conference, Grail's CEO, Bob Ragusa, revealed that the company achieved a full-year revenue of $93 million in 2023, marking a 68% YoY increase. Notably, Q4 2023 contributed $30 million to the revenue, resulting in a 44% QoQ growth rate. However, considering the Q4 2022 financial report, it is estimated that at least $5 million of the revenue came from milestone payments in pharmaceutical collaborations. Excluding this amount, the actual growth rate of Grail's commercialized screening products has declined significantly.

While revenue is crucial, early screening products, given their low market penetration, place greater emphasis on testing volume. Grail's CEO disclosed that Galleri tests had already been conducted in over 150,000 commercial applications, with more than 9,000 customers placing orders. Earlier, the company revealed that cumulative testing volume from Q3 2021 to Q3 2023 exceeded 125,000, with over 50,000 tests conducted in the first half of 2023. Considering these figures, the testing volume for 2023 would be approximately 80,000.

Comparatively, after gaining approval in August 2014, Cologuard's testing volume reached 104,000 cases in 2015. Thus, when assessing revenue and testing volume, Grail's commercial performance seems less impressive.

The Key Factors: Regulatory Approval and Insurance Coverage
All early screening products aspire to replicate the steep growth trajectory of Cologuard. Examining the success of Cologuard reveals that holding the FDA's sole early screening approval, coupled with outstanding performance and affordable pricing, facilitated its inclusion in the American Cancer Society's updated colon cancer screening guidelines. This recognition from authoritative institutions greatly aided its promotion. Moreover, just two months after FDA approval, the United States Centers for Medicare and Medicaid Services included Cologuard in the national insurance coverage, further accelerating its sales volume. Looking beyond expanded indications, Grail's current challenges primarily revolve around obtaining regulatory approval and insurance coverage.

Regarding regulatory approval, as early as 2021, the FDA requested "supplemental" clinical trials for Grail's product registration. In response, Grail initiated the Pathfinder 2 study, which involves a three-year follow-up and is expected to be completed by September next year. The CEO emphasized that Grail had already recruited 25,000 participants for the Pathfinder 2 study, which will be crucial in supporting the market pre-approval submission to the FDA for their Galleri product.

In terms of insurance coverage, Grail's IPO prospectus already outlined their estimation of payment sources. The company anticipated three categories: government insurance, commercial insurance, and out-of-pocket payments. Government insurance, covering approximately 27 million individuals, constituted the primary target group, followed by commercial insurance with 24 million individuals. The least significant group consisted of individuals paying out-of-pocket, with only around one million people. In theory, with comprehensive coverage from commercial and government insurance, Grail's product promotion should encounter minimal obstacles. However, practical considerations involve securing support from multiple payment sources.

According to the CEO's presentation, the UK National Health Service plans to review the initial data from the Galleri trial this year. If the data demonstrates positive results, the NHS may launch a pilot project involving up to onemillion participants to evaluate the feasibility and impact of implementing Galleri in the UK. This presents a significant opportunity for Grail to gain regulatory approval and insurance coverage in the UK market.

Challenges and Future Prospects
Grail's growth challenges can be attributed to various factors, including the need for regulatory approval, insurance coverage, and market penetration. The regulatory requirements set by the FDA have slowed down the commercialization process, requiring additional clinical trials for product registration. This delay has hindered Grail's ability to quickly expand its market presence and generate significant revenue.

Insurance coverage is another crucial aspect that impacts the adoption and sales of early screening products. Grail's strategy relies on securing coverage from government and commercial insurance providers to reach a wide customer base. However, navigating the complexities of reimbursement and securing support from multiple payment sources can be challenging.

Looking ahead, Grail's future prospects remain promising. The ongoing Pathfinder 2 study and the potential positive outcomes could pave the way for FDA approval and subsequent insurance coverage. Furthermore, the interest shown by the UK National Health Service indicates a potential market expansion beyond the United States. If Grail can successfully navigate these challenges and gain regulatory approval and insurance coverage, it has the potential to achieve significant growth in the coming years.

While Grail's 68% YoY revenue growth and the milestone achieved during the divestiture from Illumina are noteworthy, closer examination reveals a slowdown in commercial growth over the past year. Challenges in obtaining regulatory approval and securing insurance coverage have hindered Grail's ability to replicate the rapid growth seen in other early screening products. However, ongoing clinical trials, potential FDA approval, and interest from the UK National Health Service present opportunities for future growth. Grail's success hinges on overcoming these challenges and capitalizing on the expanding market for early cancer screening.